Cover Image
市場調查報告書

生技仿製藥 (類風濕性關節炎治療藥) - 2023年為止的預測與市場分析

Biosimilars (Rheumatoid Arthritis) - Forecast and Market Analysis to 2023

出版商 GlobalData 商品編碼 325985
出版日期 內容資訊 英文 82 Pages
訂單完成後即時交付
價格
Back to Top
生技仿製藥 (類風濕性關節炎治療藥) - 2023年為止的預測與市場分析 Biosimilars (Rheumatoid Arthritis) - Forecast and Market Analysis to 2023
出版日期: 2014年12月31日 內容資訊: 英文 82 Pages
簡介

本報告提供類風濕性關節炎治療用的生技仿製藥相關調查,提供您市場概要,競爭情形,主要藥物的詳細資訊和SWOT分析,並彙整主要藥物的銷售額預測,主要活動的影響分析,市場影響因素分析等資料。

第1章 目錄

第2章 簡介

第3章 疾病概要

  • 病因與病理學
    • 病因
    • 病理學
  • 症狀
  • 預後
  • 生活品質 (QOL)

第4章 疾病的管理

  • 疾病和治療概要
    • 診斷
    • 治療指南
    • 類風濕性關節炎治療的主要處方藥
    • 臨床診療

第5章 競爭評估

  • 概要

第6章 Inflectra/Remsima (Infliximab的生技仿製藥)

  • 概要
  • 有效性
  • 安全性
  • SWOT分析
  • 預測

第7章 生技仿製藥

  • 簡介
  • 在主要自體免疫疾病方面,Hospira的Inflectra和J & J的Remicade的比較
  • 免疫學機構團體的生技仿製藥
  • 開發中的生技仿製藥的數量
  • 製藥產業整體所感受到的生技仿製藥影響度
  • 類風濕性關節炎用生技仿製藥的普及率預計將依市場而有所不同
  • 生技仿製藥的預測
    • Etanercept的生技仿製藥
    • Adalimumab的生技仿製藥
    • Infliximab的生技仿製藥
    • Certolizumab Pegol的生技仿製藥
    • Abatacept的生技仿製藥
    • Tocilizumab的生技仿製藥
    • Rituximab的生技仿製藥

第8章 附錄

目錄
Product Code: GDHC500DFR

Rheumatoid arthritis (RA) is a chronic autoimmune disease which causes inflammation and deformity of the joints . It affects over seven million individuals in the 10MM covered in this report (US, France, Germany, Italy, Spain, UK, Japan, Australia, China, and India) and the prevalence is expected to grow to just over 8.5 million individuals by 2023. The anti-TNFs have been effective in treating the signs and symptoms of RA and inhibiting progression to erosive bone disease. However, the landscape is quickly changing with the introduction of biosimilars, novel biologics, and a class of oral therapies known as JAK inhibitors, all of which will change the market dynamics between 2013 and 2023. With the anti-TNFs as extremely effective therapies for RA, the market is extremely competitive for new entrants and will undergo further pressure as biosimilars are approved and launch.

With the cost of biologic therapies being very high, at an annual cost of at least $25,000, global healthcare systems need a reprieve from the expense. On September 9, 2013, Hospira's Inflectra and Celltrion's Remsima, which are both biosimilars of J&J's Remicade, were approved by the European Commission (EC) for marketing in the EU for multiple autoimmune diseases, including RA, Crohn's disease, ulcerative colitis, ankylosing spondylitis, and psoriatic arthritis. Remsima and Inflectra have been rolled out in selected European markets, although their launch in the 5EU is still pending due to potential intellectual property protections in these healthcare markets. The US-based generics company, Hospira, will market Inflectra in the EU, while the South Korean biotechnology company, Celltrion, the original developer of the infliximab biosimilar, will do so as well, but under the brand name Remsima, based on a collaboration forged between the two companies in 2009.

Scope

  • Overview of Rheumatoid Arthritis, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
  • Detailed information on Biosimilars including product description, safety and efficacy profiles as well as a SWOT analysis.
  • Sales forecast for Biosimilars for the top 10 countries from 2013 to 2023.
  • Sales information covered for the US, France, Germany, Italy, Spain, the UK and Japan, Australia, China and India.

Reasons to buy

  • Understand and capitalize by identifying products that are most likely to ensure a robust return.
  • Stay ahead of the competition by understanding the changing competitive landscape for Rheumatoid Arthritis.
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential.
  • Make more informed business decisions from insightful and in-depth analysis of Biosimilars performance.
  • Obtain sales forecast for Biosimilars from 2013-2023 in top 10 countries (the US, France, Germany, Italy, Spain, the UK and Japan, Australia, China and India).

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports
  • 2.3. Upcoming Related Reports

3. Disease Overview

  • 3.1. Etiology and Pathophysiology
    • 3.1.1. Etiology
    • 3.1.2. Pathophysiology
  • 3.2. Symptoms
  • 3.3. Prognosis
  • 3.4. Quality of Life

4. Disease Management

  • 4.1. Diagnosis and Treatment Overview
    • 4.1.1. Diagnosis
    • 4.1.2. Treatment Guidelines
    • 4.1.3. Leading Prescribed Drugs for the Treatment of RA
    • 4.1.4. Clinical Practice

5. Competitive Assessment

  • 5.1. Overview

6. Inflectra/Remsima (infliximab biosimilar)

  • 6.1. Overview
  • 6.2. Efficacy
  • 6.3. Safety

6.4. SWOT Analysis

  • 6.5. Forecast

7. Biosimilars

  • 7.1. Introduction
  • 7.2. Hospira's Inflectra Versus J&J's Remicade in Key Autoimmune Diseases
  • 7.3. Biosimilars in the Immunology Community
  • 7.4. By the Numbers: Biosimilars in Development
  • 7.5. The Impact of Biosimilars Will be Felt Throughout the Pharmaceutical Industry
  • 7.6. Uptake of Biosimilars for RA is Expected to Vary by Market
  • 7.7. Biosimilars' Forecast
    • 7.7.1. Etanercept Biosimilars
    • 7.7.2. Adalimumab Biosimilars
    • 7.7.3. Infliximab Biosimilars
    • 7.7.4. Certolizumab Pegol Biosimilars
    • 7.7.5. Abatacept Biosimilars
    • 7.7.6. Tocilizumab Biosimilars
    • 7.7.7. Rituximab Biosimilars

8. Appendix

  • 8.1. Bibliography
  • 8.2. Abbreviations
  • 8.3. Methodology
  • 8.4. Forecasting Methodology
    • 8.4.1. Diagnosed RA Patients
    • 8.4.2. Patent Expiry Dates
    • 8.4.3. General Pricing Assumptions
    • 8.4.4. Individual Drug Assumptions
    • 8.4.5. Generic and Biosimilar Erosion
  • 8.5. Primary Research - KOLs Interviewed for This Report
  • 8.6. Primary Research - Prescriber Survey
  • 8.7. About the Authors
    • 8.7.1. Analyst
    • 8.7.2. Reviewer
    • 8.7.3. Therapy Area Director
    • 8.7.4. Global Head of Healthcare
  • 8.8. About GlobalData
  • 8.9. Disclaimer

List of Tables

  • Table 1: Symptoms of RA
  • Table 2: 1987 ACR Diagnostic Criteria for RA
  • Table 3: 2010 ACR/EULAR Diagnostic Criteria for RA
  • Table 4: Treatment Guidelines for RA Used by Each Country in the 10MM
  • Table 5: ACR 2012 Criteria for RA Remission and Low/Moderate/High Disease Activity
  • Table 6: EULAR 2013 Criteria for RA Remission
  • Table 7: Most Prescribed Biologics for RA (After csDMARDs) in the Global Markets, 2014
  • Table 8: Leading Branded Treatments for RA 2014
  • Table 9: Product Profile - Inflectra/Remsima
  • Table 10: Inflectra/Remsima SWOT Analysis, 2014
  • Table 11: Biosimilars Pipeline for RA, 2013
  • Table 12: Physician Uptake of Biosimilar Products for RA Across the 10MM, 2014
  • Table 13: Global Sales Forecasts ($m) for Etanercept Biosimilars, 2013-2023
  • Table 14: Global Sales Forecasts ($m) for Adalimumab Biosimilars, 2013-2023
  • Table 15: Global Sales Forecasts ($m) for Infliximab Biosimilars, 2013-2023
  • Table 16: Global Sales Forecasts ($m) for Certolizumab Pegol Biosimilars, 2013-2023
  • Table 17: Global Sales Forecasts ($m) for Abatacept Biosimilars, 2013-2023
  • Table 18: Global Sales Forecasts ($m) for Tocilizumab Biosimilars, 2013-2023
  • Table 19: Global Sales Forecasts ($m) for Rituximab Biosimilars, 2013-2023
  • Table 20: Key Patent Expiries
  • Table 21: High-Prescribing Physicians (non-KOLs) Surveyed, By Country

List of Figures

  • Figure 1: Normal Synovial Joint and Synovial Joint with RA
  • Figure 2: Cellular and Cytokine Targets for the Current RA Drugs
  • Figure 3: Disease Management Flowchart for Early RA - ACR 2012
  • Figure 4: Disease Management Flowchart for Established RA - ACR 2012
  • Figure 5: Flowchart for the Management of RA - EULAR 2013
  • Figure 6: Biosimilar Prescribing Habits in RA Across the 10MM, 2014
  • Figure 7: Global Sales Forecasts ($m) for Enbrel vs. Etanercept Biosimilars, 2013-2023
  • Figure 8: Global Sales Forecasts ($m) for Humira vs. Adalimumab Biosimilars, 2013-2023
  • Figure 9: Global Sales Forecasts ($m) for Remicade vs. Infliximab Biosimilars, 2013-2023
  • Figure 10: Global Sales Forecasts ($m) for Cimzia vs. Certolizumab Pegol Biosimilars, 2013-2023
  • Figure 11: Global Sales of Orencia vs. Abatacept (IV) Biosimilars, 2013-2023
  • Figure 12: Global Sales of Actemra vs. Tocilizumab (IV) Biosimilars, 2013-2023
  • Figure 13: Global Sales of Rituxan vs. Rituximab Biosimilars, 2013-2023
Back to Top